Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Οι συνταγές μου Αποθηκεύστε τις συνταγές σας και μοιραστείτε τις εύκολα και με ασφάλεια
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Συνδρομές Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Ενδείξεις και αγωγές Βρείτε θεραπευτικές ενδείξεις και αγωγές για νόσους, συμπτώματα και ιατρικές πράξεις
Γνωρίζατε ότι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα

DANTRIUM Capsules (2018)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Dantrium Capsules 25 mg.

Qualitative and quantitative composition

Each capsule contains 25 mg dantrolene sodium. Excipient with known effect: 161.0 mg of lactose monohydrate per capsule. For a full list of excipients, see section 6.1.

Pharmaceutical form

Hard capsule. Dantrium Capsules 25 mg are presented as white/orange capsules of size 3.

Therapeutic indications

Dantrium Capsules are indicated for the treatment of chronic, severe spasticity of skeletal muscle in adults.

Posology and method of administration

Posology Dosage for Use in Spasticity for Adults For the individual patient the lowest dose compatible with optimal response is recommended. A recommended dosage increment scale is shown below: 1<sup> ...

Contraindications

Dantrium is contraindicated where spasticity is utilised to sustain upright posture and balance in locomotion or whenever spasticity is utilised to obtain or maintain increased function. Dantrium is contraindicated ...

Special warnings and precautions for use

Fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with Dantrium therapy. Patients should be instructed to contact their physician should signs or symptoms of hepatotoxicity ...

Interaction with other medicinal products and other forms of interaction

Hyperkalaemia and myocardial depression have been observed in malignant hyperthermia-susceptible patients receiving intravenous dantrolene sodium and concomitant calcium channel blockers. The effects of ...

Fertility, pregnancy and lactation

Pregnancy Although teratological studies in animals have proved satisfactory, Dantrolene sodium does cross the placenta and therefore the use of Dantrium is not advised during pregnancy. Breast-feeding ...

Effects on ability to drive and use machines

Patients should be advised not to drive a motor vehicle or undertake potentially dangerous work until Dantrium therapy has been stabilised, because some patients experience drowsiness and dizziness.

Undesirable effects

Summary of the safety profile The most frequently reported unwanted effects associated with the use of Dantrium have been drowsiness, dizziness, weakness, general malaise, fatigue and diarrhoea. These ...

Overdose

There is no known constellation of symptoms with acute overdose. Symptoms that may occur include, but are not limited to, muscular weakness, alterations in the state of consciousness (e.g. lethargy, coma), ...

Pharmacodynamic properties

Pharmacotherapeutic group: Muscle relaxants, directly acting agents ATC code: M03CA01 Mechanism of action The receptor molecule for dantrolene sodium has not been identified. Radiolabelled dantrolene sodium ...

Pharmacokinetic properties

Absorption Dantrolene sodium is easily and almost completely absorbed from the gastrointestinal tract. After dosing on an empty stomach, plasma dantrolene sodium levels peak within three hours in most ...

Preclinical safety data

Carcinogenicity Dantrolene sodium showed some evidence of tumourgenicity at high dose levels in Sprague-Dawley female rats. However, these effects were not seen in other studies in Fischer 344 rats or ...

List of excipients

Capsule content: Maize starch Talc Magnesium stearate Lactose monohydrate Capsule Shell: Gelatine Titanium dioxide (E171) Sunset yellow (E110)

Incompatibilities

Not applicable.

Shelf life

Shelf life: 3 years.

Special precautions for storage

Store below 30°C.

Nature and contents of container

Dantrium capsules are supplied in high density polyethylene (HDPE) bottles with HDPE caps. One bottle contains 100 capsules.

Special precautions for disposal and other handling

No special requirements. A patient leaflet is provided for details of use and handling of the product.

Marketing authorization holder

Norgine Pharmaceuticals Limited, Norgine House, Widewater Place, Moorhall Road, Harefield, Uxbridge, UB9 6NS, UK

Marketing authorization number(s)

PL 20011/0032

Date of first authorization / renewal of the authorization

25 October 1989

Date of revision of the text

07/09/2018

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:

Μπορείτε να υποστηρίξετε τον Γαληνό στην αποστολή του να παρέχει δωρεάν έγκυρη πληροφόρηση για κάθε φάρμακο απενεργοποιώντας το Ad Blocker για αυτόν τον ιστότοπο.